For further information concerning Lilly grant funding visit www.lillygrantoffice.com.
From Clinical Care Options (CCO), watch video featuring expert perspectives on the use of immunotherapy for HCC
Commentary by Heather McArthur, MD: clinical implications of FDA approval for pembrolizumab plus chemotherapy in PD-L1–positive advanced TNBC from CCO
Matthew Galsky, MD, discusses the evolving use of immunotherapy in urothelial carcinoma, from Clinical Care Options (CCO)
Review an expert commentary from Clinical Care Options (CCO) on choosing treatment for patients with HCC and Child-Pugh B cirrhosis